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Abstract
Introduction: Down-regulation of ex-vivo cytokine production is a specific feature in patients with sepsis. Cytokine
downregulation was studied focusing on caspase-1 activation and conversion of pro-interleukin-1b into interleukin-
1b (IL-1b).
Methods: Peripheral blood mononuclear cells were isolated from a) 92 patients with sepsis mainly of Gram-
negative etiology; b) 34 healthy volunteers; and c) 5 healthy individuals enrolled in an experimental endotoxemia
study. Cytokine stimulation was assessed in vitro after stimulation with a variety of microbial stimuli.
Results: Inhibition of IL-1b in sepsis was more profound than tumour necrosis factor (TNF). Down-regulation of IL-
1b response could not be entirely explained by the moderate inhibition of transcription. We investigated
inflammasome activation and found that in patients with sepsis, both pro-caspase-1 and activated caspase-1 were
markedly decreased. Blocking caspase-1 inhibited the release of IL-1b in healthy volunteers, an effect that was lost
in septic patients. Finally, urate crystals, which specifically induce the NLPR3 inflammasome activation, induced
significant IL-1b production in healthy controls but not in patients with sepsis. These findings were complemented
by inhibition of caspase-1 autocleavage as early as two hours after lipopolysaccharide exposure in volunteers.
Conclusions: These data demonstrate that the inhibition of caspase-1 and defective IL-1 b production is an
important immunological feature in sepsis.
Introduction
Despite the increase of our knowledge on the pathophy-
siology of sepsis, mortality remains high [1]. A vast
number of agents aiming to modulate the inflammatory
response of the host have failed to provide any clinical
benefit [2]. During the initiation of the inflammatory
process in sepsis syndrome, microbial components such
as lipopolysaccharide (LPS), muramyldipeptide (MDP),
flagellin and bacterial DNA interact with pattern recog-
nition receptors (PRRs) that are located either on the
cell membrane or in the cytoplasm of host cells. Interac-
tion of these ligands with specific PRRs leads to the acti-
vation of a series of intracellular effector molecules and
ultimately to nuclear translocation of transcription
factors such as of NF-B (Nuclear Factor kappaB) and
subsequent gene expression of pro-inflammatory cyto-
kines like TNFa (tumor necrosis factor-alpha), IL(inter-
leukin)-1b, IL-6 and IL-8 [3]. Soon after the onset of
sepsis, white blood cells (monocytes and lymphocytes)
of critically ill patients are severely impaired in their
capacity to produce these pro-inflammatory cytokines in
vitro [3]. This impairment is part of a second hypo-
inflammatory state of the septic cascade also known as
immunoparalysis. Lower expression of MHC class II and
decreased lymphocyte proliferation, as well as the induc-
tion of lymphocyte apoptosis in sepsis are also part of
the immunoparalysis state [4]. This latter stage of sepsis
is associated with an increased risk for nosocomial
infection and death.
IL-1b is a major component of the pro-inflammatory
response during sepsis [5]. IL-1b is produced as an inac-
tive pro-peptide that needs to be cleaved by the cysteine
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protease caspase-1 in order to become bioactive [6].
Procaspase-1 has to be converted into the active
cysteine protease caspase-1, which in turn cleaves pro-
IL-1b. Caspase-1 activation is mediated by the inflam-
masome, a multimeric protein platform that is activated
after recognition of danger signals such as ATP and uric
acid [7,8]. As a consequence, production of IL-1b when
sepsis appears may be modulated either at the level of
gene transcription or at the level of cleavage of pro-IL-
1b. The aim of the present study is to define if defective
production of IL-1b from monocytes in clinical sepsis is
due to down-regulation of gene expression or inhibition
of the inflammasome. To this end, we investigated the
down regulation of IL-1b in sepsis and experimental
endotoxemia in human volunteers with emphasis on the
activation of caspase-1 and subsequent IL-1b
production.
Materials and methods
Study design
This prospective study was conducted in the 4th Depart-
ment of Internal Medicine of ATTIKON University
Hospital of Athens during the period September 2007 to
September 2008. A total of 92 patients and 34 healthy
volunteers were enrolled. Written informed consent was
provided by the patients or their first-degree relatives if
patients were unable to provide the consent. The study
protocol was approved by the Ethics Committees of the
ATTIKON University Hospital. Each patient was
enrolled once.
Inclusion criteria were: a) age ≥ 18 years old; b) sepsis
due to acute pyelonephritis or primary Gram-negative
bacteremia or acute intrabdominal infection; and c)
blood sampling within 24 hours from advent of signs of
sepsis. Exclusion criteria were: a) HIV infection; b) neu-
tropenia (defined as an absolute neutrophil count lower
than 1,000 neutrophils/mm3); c) intake of corticosteroids
defined as any oral dose equal to or greater than 1 mg/
kg of equivalent prednisone for more than one month;
d) pregnancy; e) history of any organ transplantation;
and f) acute pancreatitis.
Patients with sepsis syndrome were classified as suffer-
ing from uncomplicated sepsis, severe sepsis and septic
shock, according to standard definitions [9].
Acute pyelonephritis was diagnosed in every patient
with all the following signs [10]: a) core temperature >
38°C or < 36°C; b) lumbar tenderness; and c) ≥ 10
WBC/high-power field of spun urine or ≥ 2+ in dipstick
test for WBCs and nitrates or radiological evidence con-
sistent with the diagnosis of acute pyelonephritis. Pri-
mary Gram-negative bacteremia was diagnosed in every
patient presenting with at least one peripheral blood
culture positive for Gram-negative bacteria without indi-
cation for another infection site despite thorough work-
out [11]. Acute intra-abdominal infection was diagnosed
in every patient presenting with all the following signs
[11]: a) core temperature > 38°C or < 36°C; b) WBC
count < 4,000/mm3 or > 12,000/mm3; and c) indicative
radiological evidence in abdominal computed tomogra-
phy or abdominal ultrasound.
Patients were followed for 28 days. For every patient, a
complete diagnostic work-out was performed compris-
ing history, thorough physical examination, WBC count,
blood biochemistry, arterial blood gas, blood cultures
from peripheral veins and central lines, urine cultures,
chest x-ray and chest and abdominal computed tomo-
graphy or abdominal ultrasound if considered necessary.
Endotoxemia model in healthy volunteers
The study protocol is approved by the Ethics Committee
of the Radboud University Nijmegen Medical Centre
and complies with the Declaration of Helsinki including
current revisions and the Good Clinical Practice guide-
lines. Written informed consent was obtained from all
study participants. Five subjects described in the present
study participated in a larger similar trial [12]. U.S.
reference Escherichia coli endotoxin (lot Ec-5, Center
for Biological Evaluation and Research, Food and Drug
Administration, Bethesda, MD, USA) was used. Ec-5
endotoxin, supplied as a lyophilized powder, was recon-
stituted in 5 ml saline 0.9% for injection and vortex
mixed for at least 10 minutes after reconstitution. The
endotoxin solution was administered as a single intrave-
nous bolus injection for one minute at a dose of 2 ng/
kg of body weight by one forearm vein. Patients were
observed on an intensive care unit during the entire per-
iod of the study, and blood samples were collected by
venipuncture at the time points indicated.
Isolation and stimulation of PBMCs
A total of 20 ml of heparinized blood was sampled
within less than 24 hours of advent of signs of sepsis by
venipuncture of one forearm vein under aseptic condi-
tions and processed within less than one hour. Blood
sampling was performed in a similar way from healthy
donors and just before (t = 0), two hours after (t = 2)
and eight hours after (t = 8) LPS infusion.
Heparinized venous blood was layered over Ficoll
Hypaque (Biochrom, Berlin, Germany) and centrifuged
for 20 minutes at 1,400 g. Separated mononuclear cells
(PBMCs) were washed three times with ice-cold PBS
(phosphate buffered saline) (pH: 7.2) (Biochrom) and
counted in a Neubauer chamber. Their viability was
more than 99% as assessed by trypan blue exclusion of
dead cells. They were then diluted in RPMI 1640
enriched with 2 mM of L-glutamine, 100 U/ml of peni-
cillin G, 100 μg/ml of gentamicin and 10 mM of pyru-
vate and suspended in wells of a 96-well plate (Greiner,
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Alphen a/d Rijn, The Netherlands). The final volume
per well was 200 μl with a density of 2 × 106 cells/ml.
PBMCs were stimulated with the following stimuli:
a) LPS of Escherichia coli O55:H5 at concentrations
of 0.1 and 10 ng/ml (Sigma Co, St. Louis, MO,
USA), which is a TLR4 agonist;
b) 5 μg/ml of Pam3Cys-SKKK (EMC Microcollec-
tions, Tübingen, Germany) which is a TLR2 agonist;
c) 5 μg/ml of phytohemagglutin (PHA) of Phaselolus
vulgaris (PHA-L, Roch Diagnostics GMBH, Man-
nheim, Germany);
d) 5 × 105 colony-forming units (CFU)/ml of heat-
killed isolates of Candida albicans, of Pseudomonas
aeruginosa and of methicillin-resistant Staphylococ-
cus aureus (MRSA). All are blood isolates from
patients with severe sepsis killed after heating a 5 ×
107 CFU/ml inoculum for six hours at 90°C. Pseudo-
monas aeruginosa isolate is already applied in former
studies of our group [13]. It is multidrug-resistant to
piperacillin/tazobactam, imipenem, amikacin and
ciprofloxacin, as assessed after estimation of mini-
mum inhibitory concentrations by a microdilution
technique using CLSI breakpoints. Resistance to
methicilln of the MRSA isolate was assessed after
detection of the mecA gene by PCR [14]. For all
three isolates heat-killing was ascertained after six
serial 1:10 dilutions of the inactivated inoculum.
e) crystals of MSU at concentrations of 10 and 100
μg/ml prepared as described elsewhere [15].
Stimulations were performed in the absence and pre-
sence of 5 μmol/l of the caspase-1 inhibitor (ICE-i) Ac-
Tyr-Val-Ala-Asp-2,6-dimethylbezoyloxymethylketone
(YVAD). YVAD was purchased from Biomol (Plymouth
Meeting, USA) and solubilized in dimethyl sulfoxide
(DMSO) at 10 mg/ml.
PBMCs of healthy subjects before and during experi-
mental endotoxemia were stimulated without/with 10
ng/ml of LPS, as described above.
After 24 hours of incubation at 37°C in 5% CO2 atmo-
sphere, the plates were centrifuged. Supernatants were
kept stored at -70°C until assayed.
Cytokine measurements
Concentrations of IL-1b, IL-6 and ΤNFa were estimated
in supernatants in duplicate by an enzyme immunoassay
(R&D Systems, Minneapolis, MN, USA). The lower
detection limits were: 20 pg/ml for IL-1b; 20 pg/ml for
IL-6; and 40 pg/ml for TNFa. Concentrations of IL-10
were also determined in supernatants of LPS-stimulated
PBMCs of 44 sepsis patients by an enzyme immunoas-
say (R&D Systems). The lower detection limit was 20
pg/ml.
Western blot analysis for caspase-1
A total of 5 × 106 PBMCs from four healthy controls;
from five patients with sepsis; and from four healthy
volunteers before LPS infusion (t = 0) and two hours
after infusion (t = 2) were lysed in 100 μl lysis buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2
mM EGTA, 10% glycerol, 1% Triton X-100, 40 mM b-
glycerophosphate, 50 mM sodium fluoride, 200 μM
sodium vanadate, 10 μg/ml leupeptin, 10 μg/ml aproti-
nin, 1 μM pepstatin A, and 1 mM phenylmethylsulfonyl
fluoride) and stored at -70°C. Protein concentrations
were determined by BCA protein assay (Thermo Scienti-
fic, Rockford, IL, USA) before loading on a 12% SDS-
bisacrylamide gel (Bio-Rad, Hercules, CA, USA) and
anti-actin-antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Proteins were transferred onto a nitro-
cellulose membrane by using an I-Blot apparatus (Invi-
trogen, Carlsbad, CA, USA). Rabbit-anti-caspase-P10
antibody (Santa Cruz Biotechnology) was used followed
by goat-anti-rabbit-Alexa680 (LI-COR Biosciences, Lin-
coln, NE, USA). The protein bands were visualized by
an infrared image scanner (Odyssey, Westburg, The
Netherlands).
Quantitative PCR for mRNA expression of TNFa and IL-1b
PBMCs were stimulated, as stated above, with or with-
out 1 ng/ml of LPS. After four hours of incubation at
37°C in 5% CO2 and plate centrifugation, the cell pellet
was lysed with 400 μl of Trizol (Invitrogen, Karlsruhe,
Germany) and kept at -80°C until extraction of RNA.
RNA was extracted by chloroform gradient centrifuga-
tion followed by treatment for 30 minutes at 37°C with
0.04 U/μl of DNAase (Ambion, Austin, USA). A total of
1.5 μg of RNA was applied for the production of cDNA
using 0.4 mM of dNTPs (New England BioLabs, Ips-
witch, MA, USA), 1 U of RNA-sin (New England Bio-
Labs), 10 mM DTT (New England BioLabs) and 5× of
the reverse transcriptase buffer in a Mastercycler 5330
apparatus using appropriate blanks (Eppendorf, Antisel,
Athens, Greece). After an initial incubation step of 10
minutes at 65°C, 1 μU of reverse transcriptase (New
England BioLabs) was added followed by three steps: 10
minutes at 25°C; 50 minutes at 42°C; and 15 minutes at
70°C. cDNA was kept at -80°C until assayed.
Expression of mRNA was tested by the iCycler system
(BioRad) using per reaction tube 1 μl of cDNA, 0.1 mg/
ml of sense and antisense primers, 3 mM of MgCl2
(New England BioLabs), 0.25 mM of dNTPs (New Eng-
land BioLabs), 10× buffer and 1 mM of Taq polymerase
with SYBR-Gr as a fluorochrome. Primer sequences
were: for TNFa sense 5’-TGG CCC AGG CAG TCA
GA-3’ and antisense 5’-GGT TTG CTA CAA CAT
GGG CTA CA-3’; for IL-1b sense 5’-GCC CTA AAC
AGA TGA AGT GCT C-3’ and antisense 5’-GAA CCA
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GCA TCT TCC TCA G-3’; and for b2-microglobulin
sense 5’-ATG AGT ATG CCT GCC GTG TG-3’ and
antisense 5’-CCA AAT GCG GCA TCT TCA AAC-3’.
After an initial denaturation step for 10 minutes at 95°
C, 34 cycles were performed. Each cycle consisted of
three steps; denaturation for 30 seconds at 95°C; anneal-
ing for 30 seconds at 72°C; and elongation for 30 sec-
onds at 95°C. Amplification was followed by a melting
curve; appropriate blanks were applied. The PCR pro-
duct was recognized after 3% agarose gel electrophoresis
and ethidium bromide staining. Quantitative results
were expressed as defined by the PFAFFL equation [15]
using the efficiency of a standard curve created with
known cDNA.
Statistical analysis
Results were expressed as means ± SE. Distribution of
cytokine concentrations after stimulation within the
healthy control group, the uncomplicated sepsis group,
the severe sepsis group and the septic shock group was
normal; comparisons between groups were done by
ANOVA with post hoc analysis by Bonferroni to avoid
any random correlation. Comparisons of a) mRNA tran-
scripts; and b) cytokine release after stimulation with
both LPS and MSU between controls and patients were
done by the Mann-Whitney U test. Comparisons of a)
cytokine release before and after treatment with the
YVAD inhibitor; and b) cytokine release before and
after treatment with MSU were done by the Wilcoxon’ s
signed rank test. P-values below 0.05 were considered
significant.
Results
Study population
Demographic and clinical characteristics of the 92 septic
patients are shown in Table 1. Forty-nine patients were
classified as uncomplicated sepsis, 26 as severe sepsis
and 17 as septic shock. Of the 34 healthy donors, 18
were male and 14 female; their mean age was 33.20 ±
5.51 years (mean ± SD).
Cytokine production ex vivo
The concentration of pro-inflammatory cytokines in
supernatants of PBMCs isolated from septic patients
after stimulation with the various bacterial components
was significantly reduced compared to healthy controls
(Figure 1). The severity of sepsis was reflected by the
degree of cytokine production: PBMCs isolated from
patients with septic shock produced less cytokines than
those of patients with severe sepsis, which in turn pro-
duced less than those from patients with uncomplicated
sepsis. Production of IL-1b and of IL-6 was impaired
after stimulation with LPS and with heat-killed bacteria
but not after stimulation with Pam3Cys and PHA. This
was found for all disease stages (panels A, B, D and E).
Down-regulation of IL-1b and of IL-6 followed a differ-
ent pattern than TNFa; release of TNFa was not
impaired after LPS stimulation of PBMCs of patients
with uncomplicated sepsis and with severe sepsis; more-
over after stimulation with heat-killed bacteria TNFa
production in uncomplicated sepsis did not differ from
controls (panels C and F). IL-10 in supernatants of LPS-
stimulated PBMCs from 14 patients with uncomplicated
sepsis, 12 patients with severe sepsis and 18 patients
with septic shock was below the limit of detection (data
not shown), showing that the release of IL-10 did not
differ within the stages of sepsis in a similar way as pro-
inflammatory cytokines differed.
These findings led us to hypothesize that inhibition of
ex vivo cytokine release by PBMCs in clinical sepsis is
modulated in different ways for IL-1b and for TNFa
after stimulation with LPS. This is supported by the
finding that the release of IL-6 followed IL-1b, as
expected [6].
One explanation for the reduced production of cyto-
kines during sepsis is that transcription of proinflamma-
tory cytokines is reduced. Therefore, the number of
RNA transcripts of TNFa and of IL-1b in the cell
lysates of PBMCs of four healthy volunteers and of six
septic patients was determined (Figure 2). Although
transcripts of PBMCs of septic patients were lower in
the case of TNFa, they only showed a moderate
Table 1 Demographic and clinical characteristics of the
92 septic patients enrolled in the study
Gender (male/female) 48/44
Age (years, mean ± SD) 65.59 ± 19.88
APACHE II score (mean ± SD) 14.36 ± 7.48
Sepsis stage (number, %)
Uncomplicated sepsis 49 (53.3)
Severe sepsis 26 (28.3)
Septic shock 17 (18.5)
Underlying infection (number, %)
Acute pyelonephritis 38 (41.3)
Primary bacteremia 27 (29.3)
Acute intrabdominal infections 27 (29.3)
Co-morbidities (number, %)
Diabetes melliitus type 2 15 (16.3)
Chronic obstructive pulmonary disease 6 (6.5)
Chronic renal failure 9 (9.8)
Chronic heart failure 7 (7.6)
Implicated pathogen* (number, %)
Escherichia coli 21 (22.8)
Klebsiella pneumoniae 11 (11.9)
Other Gram-negatives 11 (11.9)
Death (number, %) 22 (23.9)
*isolates either in blood or urine. APACHE, Acute Physiology and Chronic
Health Evaluation.
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Figure 1 Release of pro-inflammatory cytokines by PBMCs of healthy controls (Con, n = 14) and of septic patients. Patients are classified
as sepsis (S, n = 14), severe sepsis (SS, n = 18) and septic shock (Sch, n = 11). Cells were stimulated with 10 ng/ml of lipopolysaccharide of
Escherichia coli O55:H5 (LPS); with 5 μg/ml of Pam3Cys; and with 5 μg/ml of phytohemmaglutin (PHA) (A, B and C); and with 5 × 105 cfu/ml of
heat-inactivated isolates of Candida albicans, of multidrug-resistant Pseudomonas aeruginosa and of methicillin-resistant Staphylococcus aureus (D,
E and F). Asterisks denote statistically significant differences compared with the respective healthy controls.
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decrease of IL-1b mRNA compared to healthy controls,
and this difference was not statistically significant. It is
therefore tempting to hypothesize that additional
mechanisms are involved in the inhibition.
Caspase-1 in sepsis and after LPS infusion
IL-1b is not only regulated at the level of transcription,
but also at the level of processing of pro-IL-1b by cas-
pase-1 [6]. Therefore, we performed Western blot analy-
sis of caspase-1. As shown by the Western blot
presented in Figure 3A, B, the amount of both pro-cas-
pase-1 and caspase-1 is diminished in sepsis. Since sep-
sis in this series of patients was mainly caused by Gram-
negative bacteria (Table 1), we also investigated caspase-
1 activity in volunteers injected intravenously with LPS.
As depicted in Figure 3C, caspase-1 activation was
markedly decreased in cell lysates of these volunteers.
The decrease in caspase-1 was accompanied by near
complete absence of IL-1b production by PBMCs stimu-
lated ex vivo with LPS. The effect of LPS infusion on IL-
1b production was partially restored eight hours after
the infusion (Figure 3D).
If the reduced caspase-1 activity is responsible for the
decreased production of IL-1b, blocking caspase-1 in
septic patients would have limited or no effect. Indeed,
caspase-1 inhibition with the caspase-1 inhibitor YVAD
had no effects on IL-1b production when PBMCs iso-
lated from patients with sepsis were stimulated with
LPS (Figure 4). Monosodium urate (MSU) is able to
activate the NLPR3 inflammasome, resulting in caspase-
1 activation [7]. To investigate whether NLPR3-stimu-
lated activation of caspase-1 activation was impaired, we
used MSU as a stimulus. Stimulation with MSU in the
presence of LPS resulted in release of IL-1b from
PBMCs isolated from healthy controls, but not from
PBMCs of patients with sepsis (Figure 5). We have pre-
viously observed that LPS at very low concentrations of
0.1 ng/ml synergizes with MSU (0.1 ng/ml) to induce
excess release of IL-1b but not of TNFa [15]. Although
this synergy was depicted here in healthy volunteers, it
was lost in sepsis patients (Figure 6).
Discussion
In this study of patients with sepsis and of human
volunteers exposed to intravenous endotoxin, we show
that production of cytokines ex vivo is generally down-
regulated proportionally to the severity of sepsis. The
pattern of production of IL-1b is different from that
with TNFa, as IL-1b is being down-regulated both in
severe sepsis and in uncomplicated sepsis, while TNFa
production is sustained in this last category of patients.
Because of the only moderate decrease in IL-1b
mRNA, we hypothesized that single inhibition of tran-
scription cannot explain the decreased IL-1b produc-
tion and the differential regulation of TNFa and IL-1b.
This led us to investigate caspase-1 activity. We
demonstrated that active caspase-1 which cleaves pro-
IL-1b into bioactive IL-1b, was nearly absent in
patients with sepsis or in volunteers receiving an LPS
infusion. In line with that, stimulation of the NLPR3
inflammasome by uric acid crystals was significantly
impaired in patients with sepsis. Part of the impaired
activation of the NLPR3 inflammasome may be due to
the very low amount of procaspase-1 seen in sepsis
patients. However, the amount of procaspase-1 was
less affected in experimental endotoxemia probably
showing that conversion of procaspase-1 to caspase-1
was affected.
Figure 2 mRNA transcripts after stimulation of PBMCs of four healthy controls and of six patients with sepsis syndrome. Cells were
stimulated with 10 ng/ml of lipopolysaccharide of Escherichia coli O55:H5.
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Figure 3 Western blots of lysates of PBMCs of patients with sepsis and of volunteers with endotoxemia. Blots show that cleaved
caspase-1 is lost in sepsis. (A) one healthy control and one patient with sepsis (data representative of five sepsis patients tested); (B) quantitative
assessment of blots of lysates of PBMCs for four healthy volunteers and for five patients with sepsis; (C) Western blots of caspase-1 before and
two hours after in vivo LPS infusion in one healthy volunteer (representative of four volunteers). (D) IL-1b production by LPS-stimulated PBMCs
isolated at t = 0, t = 2 and t = 8 hours after LPS infusion in healthy volunteers.
Figure 4 Release of pro-inflammatory cytokines from PBMCs of 13 healthy controls and of 40 septic patients. Patients with sepsis (n =
20,) with severe sepsis (n = 14) and septic shock (n = 6) are encountered together. Cells were stimulated with 10 ng/ml of lipopolysaccharide of
Escherichia coli O55:H5 in the absence or presence of caspase-1 inhibitor. Asterisks denote statistically significant differences of respective
comparisons in the absence of inhibitor.
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Down regulation of ex vivo cytokine production is well
documented in patients with sepsis [16-18], in patients
with severe infections [19] and after experimental endo-
toxin challenge [12]. This phenomenon has been given
several names in the literature, although it is not entirely
clear whether it regards the same process. The older lit-
erature describes it as endotoxin tolerance; another
name is immunoparalysis. In the description of the lat-
ter, a lot of weight is given to impaired T-cell dependent
adaptive immune responses associated with decreased
expression of MHC class II, decreased lymphocyte pro-
liferation and T-cell apoptosis [20-22], but the patho-
physiological relevance of these features is unclear.
Previous studies have reported down-regulation of cyto-
kine production from monocytes of septic patients after
stimulation with selective TLR agonists [16-19]. We
demonstrate here that the down-regulation occurs irre-
spective of the stimulant, being either microbes or
microbial components. Impaired cytokine production
after stimulation with heat-killed whole microorganisms
is described for the first time, to our knowledge, and it
is of considerable pathophysiological significance for
four reasons: a) heat-killed whole microorganisms con-
tain a broad panel of PAMPs; b) the applied microor-
ganisms are blood isolates from septic patients; c)
impairment of cytokine response is indicative of a pre-
disposition of the septic host for super-infections; and
d) many clinical trials have been conducted with the
application of agents aiming to suppress the over-activ-
ity of the pro-inflammatory cascade in sepsis [2]. The
present results denote that during the clinical course of
sepsis the opposite phenomenon occurs with down-reg-
ulation of the release of pro-inflammatory cytokines by
circulating monocytes and may explain, at least in part,
the failure of most of these trials.
Down-regulation of cytokine production was accom-
panied by reduced transcription of pro-inflammatory
cytokines as a mechanism underlying the decreased
cytokine production, confirming findings of others
[16,17]. As already described elsewhere [19], inhibition
Figure 5 Release of pro-inflammatory cytokines from PBMCs of 13 healthy controls and of 40 septic patients. Patients with sepsis (n =
20), with severe sepsis (n = 14) and with septic shock (n = 6) are encountered together. Cells were stimulated with 100 μg/ml of monosodium
urate (MSU) in the presence of 10 ng/ml of lipopolysaccharide of Escherichia coli O55:H5 (LPS). P signifies statistical differences between patients.
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of transcription was moderate for IL-1b mRNA whereas
production was inhibited up to 90%, suggesting that
additional mechanisms are involved. As mentioned
above, we found that caspase-1 activation was decreased
in sepsis and after endotoxin challenge. This, together
with the lesser transcription of IL-1b, may well explain
its decreased production. Our finding regarding caspase-
1 protein are in accordance with a recent report show-
ing that mRNA expression of the inflammasome com-
ponents ASC and caspase-1 is reduced in monocytes of
patients with septic shock [23]. Caspase-1 activation is
constitutively present in human primary monocytes iso-
lated from healthy volunteers [24], yet it is absent in
patients with sepsis syndrome, as shown in the present
study.
One would expect that microbial components in sep-
sis trigger the inflammasome, at least initially. In con-
trast, the activation of the inflammasome ceases pretty
soon after the onset of sepsis. It is noteworthy that
already two hours after LPS infusion down-regulation of
caspase-1 occurs. At that stage, we document decreased
conversion from pro-caspase-1 to caspase-1, and the
timeframe may preclude a notable effect on transcrip-
tion and translation of pro-caspase-1. The immunoblots
of the sepsis patients, however, are compatible with
decreased transcription and translation of caspase-1, as
reported by Fahy et al. [23]. In addition, we found that
white blood cells of septic patients did not respond
properly to urate crystals, a trigger of the NLPR3
inflammasome. The observed decreased of IL-1b pro-
duction may also explain why IL-6 followed similar
kinetics whereas TNFa does not since IL-1b regulates
production of IL-6 [6].
Whether the decreased caspase-1 activity is a benefi-
cial compensatory mechanism is currently unclear. On
the one hand, in experimental models caspase-1
Figure 6 Release of pro-inflammatory cytokines from PBMCs of 10 healthy controls and of 25 septic patients. Patients with sepsis (n =
12) with severe sepsis (n = 10) and with septic shock (n = 3) are encountered together. Cells were stimulated with single 0.1 ng/ml of
lipopolysaccharide of Escherichia coli O55:H5 (LPS) or its interaction with 10 μg/ml of monosodium urate (MSU). Asterisks denote statistically
significant differences compared with single LPS.
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activation contributes to mortality during Gram-negative
sepsis, as caspase-1 deficient mice are protected against
LPS-induced systemic inflammation and E. coli-induced
lethal peritonitis [25,26]. On the other hand, caspase-1
activation of IL-1b and IL-18 also represents protective
host defense mechanisms, and their inactivation may
well be an important component of immunoparalysis in
sepsis.
Conclusions
This study documenting decreased activation of caspase-
1 and inhibited cytokine responses in septic patients and
in volunteers exposed to intravenous endotoxin provides
new insights into the mechanism of cytokine down-reg-
ulation in sepsis patients. Further investigations are
needed to assess whether these findings can be exploited
in therapeutic interventions.
Key messages
• Blood monocytes of patients with sepsis are char-
acterized by impaired release of pro-inflammatory
cytokines after ex vivo stimulation. This impairment
is related with disease severity and it is particularly
pronounced for IL-1b.
• Defective ex vivo release of IL-1b is related not
only with reduced gene transcription but also with
reduced activation of the inflammasome.
Abbreviations
CFU: colony-forming units; DMSO: dimethyl sulfoxide; HIV: human
immunodeficiency virus; IL-1β: interleukin-1beta; IL-6: interleukin-6; LPS:
lipopolysaccharide; MDP: muramyldipeptide; MSU: monosodium urate;
PBMCs: peripheral blood mononuclear cells; PBS: phosphate buffered saline;
PCR: polymerase chain reaction; PHA: phytohemagglutin; PRRs: pattern
recognition receptors; TNFα: tumour necrosis factor-alpha; WBCs: white
blood cells.
Acknowledgements
MGN was supported by a Vici grant of the Netherlands Organization for
Scientific Research.
Author details
14th Department of Internal Medicine, University of Athens, Medical School,
1 Rimini Str. 12462 Athens, Greece. 2Department of Medicine and Nijmegen
Institute for Infection, Inflammation and Immunity (N4i), Radboud University
Nijmegen Medical Centre, 8 Geert Grooterplein, 6500 HB Nijimegen, The
Netherlands. 3Department of Critical Care Medicine, Radboud University
Nijmegen Medical Centre, 8 Geert Grooterplein, 6500 HB Nijimegen, The
Netherlands.
Authors’ contributions
EJGB designed the study in patients with sepsis, performed statistical
analysis, and wrote the manuscript. FLV performed cell stimulation and
Western blot analysis in experimental endotoxemia and Western blot
analysis in human sepsis, and drafted the manuscript. MM performed
quantitative PCR analysis, cell stimulations in patients with sepsis, and
drafted the manuscript. MR, AA and AS collected clinical data, and drafted
the manuscript. LABJ designed the study of human endotoxemia, and
drafted the manuscript. PP conducted the experiments of experimental
endotoxemia, and drafted the manuscript. MG performed cytokine
measurements and drafted the manuscript. JWMM and MGN designed the
study of human sepsis, and drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2010 Revised: 19 December 2010
Accepted: 18 January 2011 Published: 18 January 2011
References
1. Remick DG: Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444.
2. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory
therapies in severe sepsis and septic shock. Clin Infect Dis 2002,
34:1084-1093.
3. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis.
Nat Rev Immunol 2008, 8:776-787.
4. Frazier WJ, Hall MW: Immunoparalysis and adverse outcomes from critical
illness. Pediatr Clin North Am 2008, 55:647-668.
5. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der
Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, et al: Circulating
interleukin-1 and tumor necrosis factor in septic shock and experimental
endotoxin fever. J Infect Dis 1990, 161:79-84.
6. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996,
87:2095-2147.
7. Pétrilli V, Dostert C, Muruve DA, Tschopp J: The inflammasome: a danger
sensing complex triggering innate immunity. Curr Opin Immunol 2007,
19:615-655.
8. Drenth JPH, van der Meer JWM: The inflammasome-a linebacker of innate
defense. N Engl J Med 2006, 355:730-732.
9. Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS
international sepsis definitions conference. Crit Care Med 2003,
31:1250-1256.
10. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical
diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-151.
11. Calandra T, Cohen J, International Sepsis Forum Definition of Infection in
the ICU Consensus Conference: The International Sepsis Forum
Consensus definitions of infections in the intensive care unit. Crit Care
Med 2005, 33:1538-1548.
12. Draisma A, Bemelmans R, van der Hoeven JG, Spronk P, Pickkers P:
Microcirculation and vascular reactivity during endotoxemia and
endotoxin tolerance in humans. Shock 2009, 31:581-585.
13. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V,
Mouktaroudi M, Perrea D, Karayannacos PE, Giamarellou H:
Immunomodulatory clarithromycin treatment of experimental sepsis and
acute pyelonephritis caused by multidrug-resistant Pseudomonas
aeruginosa. Antimicrob Agents Chemother 2004, 48:93-99.
14. Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U: Methicillin-resistant
Staphylococcus aureus containing the Panton-Valentine leucocidin gene
in Germany in 2005 and 2006. J Antimicrob Chemother 2007, 60:1258-1263.
15. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J,
Kullberg BJ, Netea MG, van der Meer JW: Crystals of monosodium urate
monohydrate enhance lipopolysaccharide-induced release of
interleukin-1β through a caspase-1 mediated process. Ann Rheum Dis
2009, 68:273-278.
16. Schultz MJ, Olszyna DP, de Jonge E, Verbon A, van Deventer SJH, van der
Poll T: Reduced ex vivo chemokine production by polymorphonuclear
cells after in vitro exposure of normal humans to endotoxin. J Infect Dis
2000, 182:1264-1267.
17. van Deuren M, Netea MG, Hijmans A, Demacker PN, Neeleman C,
Sauerwein RW, Bartelink AK, van der Meer JW: Posttranscriptional down-
regulation of tumor necrosis factor-alpha and interleukin-1beta
production in acute meningococcal infections. J Infect Dis 1998,
177:1401-1405.
18. Keuter M, Dharmana E, Gasem MH, van der Ven-Jongekrijg J,
Djokomoeljanto R, Dolmans WM, Demacker P, Sauerwein R, Gallati H, van
der Meer JW: Patterns of proinflammatory cytokines and inhibitors
during typhoid fever. J Infect Dis 1994, 169:1306-1311.
19. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O,
Schildberg FW: Downregulation of proinflammatory cytokine release in
whole blood from septic patients. Blood 1995, 85:1341-1347.
Giamarellos-Bourboulis et al. Critical Care 2011, 15:R27
http://ccforum.com/content/15/1/R27
Page 10 of 11
20. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A:
Marked elevation of human circulating CD4+CD25+ regulatory T cells in
sepsis-induced immunoparalysis. Crit Care Med 2003, 31:2068-2071.
21. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE:
Accelerated lymphocyte death in sepsis occurs by both the death
receptor and mitochondrial pathways. J Immunol 2005, 174:5110-5118.
22. Unsinger J, Herdon JM, Davis CG, Muenzer JT, Hotchkiss RS, Ferguson TA:
The role of TCR engagement and activation-induced cell death in
sepsis-induced T cell apoptosis. J Immunol 2006, 177:7968-7673.
23. Fahy RJ, Exline MC, Gavrilin MA, Bhatt NY, Besecker BY, Sarkar A,
Hollyfield JL, Duncan MD, Nagaraja HN, Knatz NL, Hall M, Wewers MD:
Inflammasome mRNA expression in human monocytes during early
septic shock. Am J Resp Crit Care Med 2008, 177:983-988.
24. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH,
van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ,
Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA: Differential
requirement for the activation of the inflammasome for processing and
release of IL-1beta in monocytes and macrophages. Blood 2009,
113:2324-2335.
25. Li P, Allen H, Banerjee S, Seshadri T: Characterization of mice deficient in
interleukin-1 beta converting enzyme. J Cell Biochem 1997, 64:27-32.
26. Sarkar A, Hall MW, Exline M, Hart J, Knatz N, Gatson NT, Wewers MD:
Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis
independently of interleukin-1beta and interleukin-18. Am J Respir Crit
Care Med 2006, 174:1003-1010.
doi:10.1186/cc9974
Cite this article as: Giamarellos-Bourboulis et al.: Inhibition of caspase-1
activation in gram-negative sepsis and experimental endotoxemia. Critical
Care 2011 15:R27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Giamarellos-Bourboulis et al. Critical Care 2011, 15:R27
http://ccforum.com/content/15/1/R27
Page 11 of 11
